Mbx Biosciences Inc (MBX)

$32.99 +0.70 (2.17%)
Market Cap 1.57B
Revenue (ttm) 0.00
Net Income (ttm) -86.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 601,600
Avg Vol 591,754
Day's Range N/A - N/A
Shares Out 47.51M
Stochastic %K 91%
Beta 1.25
Analysts Strong Sell
Price Target $62.55

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 317 659 0200
Website: mbxbio.com
Address:
11711 North Meridian Street, Suite 300, Carmel, United States
LewisDaKat
LewisDaKat Apr. 3 at 12:31 PM
$MBX MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://marketwirenews.com/stock/mbx/news/mbx-biosciences-reports-inducement-grant-under-nasda-8891755499107440.html?utm_source=stocktwits
0 · Reply
samjoyst
samjoyst Apr. 2 at 2:31 PM
$MBX anyone noticing a strange pattern today?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 26 at 1:41 PM
$MBX RSI: 38.64, MACD: -1.7043 Vol: 1.59, MA20: 29.47, MA50: 34.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Just_me_idea
Just_me_idea Mar. 24 at 8:56 PM
$MBX Promising biotech with a peptide platform applicable across multiple indications, including obesity, strong Phase 2 results, and an upcoming very short Phase 3 — assuming it isn’t acquired before then. Cash secured. And to top it off, Karen Basbaum, the serial deal‑maker, just joined as CBO — guess why…
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Mar. 16 at 2:05 PM
$MBX CEO purchased 18,500 shares at $28.41 for a total of $525,663. Hawryluk P. Kent now owns 1,215,051 shares. https://ceo-buys.com
0 · Reply
Tomakak
Tomakak Mar. 13 at 2:38 PM
$MBX another dilution ahead, why? They have cash till 2029
0 · Reply
Benalish
Benalish Mar. 10 at 5:57 PM
$MBX
0 · Reply
Quantumup
Quantumup Mar. 2 at 12:23 PM
H.C. Wainwright⬆️ $GPCR's PT to $114 from $90 and reiterated at a Buy rating. $VKTX $LLY $NVO $MBX AZN AMGN RHHBY PFE Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2028443691505914151?s=20
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 12:23 PM
$MBX Current Stock Price: $34.80 Contracts to trade: $35.0 MBX Mar 20 2026 Call Entry: $2.50 Exit: $4.39 ROI: 76% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PamelaBarbieri520
PamelaBarbieri520 Feb. 21 at 7:19 AM
$MBX Microcap with limited disclosure and speculative trading. Fundamentals are unclear. Liquidity risk remains high.
0 · Reply
Latest News on MBX
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 3, 2026, 8:00 AM EDT - 2 days ago

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript

Mar 25, 2026, 3:25 PM EDT - 10 days ago

Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Mar 12, 2026, 8:00 AM EDT - 24 days ago

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

Mar 10, 2026, 8:00 AM EDT - 26 days ago

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

Mar 9, 2026, 10:21 AM EDT - 26 days ago

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

Mar 9, 2026, 8:00 AM EDT - 27 days ago

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

MBX Biosciences to Participate in Upcoming March Investor Conferences

Feb 23, 2026, 8:00 AM EST - 5 weeks ago

MBX Biosciences to Participate in Upcoming March Investor Conferences

Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript

Feb 12, 2026, 1:54 PM EST - 7 weeks ago

Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript

MBX Biosciences to Participate in Upcoming Investor Conferences

Feb 11, 2026, 8:00 AM EST - 7 weeks ago

MBX Biosciences to Participate in Upcoming Investor Conferences

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

Jan 22, 2026, 8:00 AM EST - 2 months ago

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

MBX Biosciences, Inc. (MBX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:26 PM EST - 2 months ago

MBX Biosciences, Inc. (MBX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 4:00 PM EST - 2 months ago

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

Microbix Biosystems Inc. (MBX:CA) Q4 2025 Earnings Call Transcript

Dec 18, 2025, 1:47 PM EST - 3 months ago

Microbix Biosystems Inc. (MBX:CA) Q4 2025 Earnings Call Transcript

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

Dec 15, 2025, 8:00 AM EST - 3 months ago

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 4 months ago

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 6, 2025, 8:00 AM EST - 5 months ago

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 5 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MDGL MEDI

MBX Biosciences to Participate in November Investor Conferences

Oct 20, 2025, 8:00 AM EDT - 5 months ago

MBX Biosciences to Participate in November Investor Conferences

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Sep 29, 2025, 8:00 AM EDT - 6 months ago

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Sep 25, 2025, 8:24 AM EDT - 6 months ago

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

RIG SFIX

MBX Biosciences, Inc. - Special Call

Sep 24, 2025, 9:27 PM EDT - 6 months ago

MBX Biosciences, Inc. - Special Call

MBX Biosciences Announces Pricing of Upsized Public Offering

Sep 24, 2025, 9:15 PM EDT - 6 months ago

MBX Biosciences Announces Pricing of Upsized Public Offering

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

Sep 22, 2025, 5:10 PM EDT - 6 months ago

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

MBX Biosciences Announces Proposed Public Offering

Sep 22, 2025, 4:14 PM EDT - 6 months ago

MBX Biosciences Announces Proposed Public Offering

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Sep 22, 2025, 7:00 AM EDT - 6 months ago

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Sep 19, 2025, 4:18 PM EDT - 7 months ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Sep 4, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 2:00 PM EDT - 8 months ago

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Jun 23, 2025, 8:00 AM EDT - 10 months ago

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

Jun 16, 2025, 8:00 AM EDT - 10 months ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

Jun 10, 2025, 8:00 AM EDT - 10 months ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

May 31, 2025, 7:24 AM EDT - 11 months ago

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences to Participate in June Investor Conferences

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

Apr 22, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 17, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

MBX Biosciences Announces Additions to Leadership Team

Mar 5, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Additions to Leadership Team

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Mar 3, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

MBX Biosciences to Participate in March Investor Conferences

Feb 18, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences to Participate in March Investor Conferences

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Jan 7, 2025, 7:00 AM EST - 1 year ago

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Nov 18, 2024, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

MBX Biosciences to Participate in Upcoming November Investor Conferences

Oct 28, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Upcoming November Investor Conferences

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 16, 2024, 4:05 PM EDT - 1 year ago

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Sep 14, 2024, 5:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

BCAX GLXG TDTH XCH ZBIO

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Sep 13, 2024, 12:36 PM EDT - 1 year ago

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

MBX Biosciences raises $163.2 mln in US IPO

Sep 12, 2024, 7:20 PM EDT - 1 year ago

MBX Biosciences raises $163.2 mln in US IPO

MBX Biosciences Announces Pricing of Initial Public Offering

Sep 12, 2024, 7:11 PM EDT - 1 year ago

MBX Biosciences Announces Pricing of Initial Public Offering

LewisDaKat
LewisDaKat Apr. 3 at 12:31 PM
$MBX MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://marketwirenews.com/stock/mbx/news/mbx-biosciences-reports-inducement-grant-under-nasda-8891755499107440.html?utm_source=stocktwits
0 · Reply
samjoyst
samjoyst Apr. 2 at 2:31 PM
$MBX anyone noticing a strange pattern today?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 26 at 1:41 PM
$MBX RSI: 38.64, MACD: -1.7043 Vol: 1.59, MA20: 29.47, MA50: 34.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Just_me_idea
Just_me_idea Mar. 24 at 8:56 PM
$MBX Promising biotech with a peptide platform applicable across multiple indications, including obesity, strong Phase 2 results, and an upcoming very short Phase 3 — assuming it isn’t acquired before then. Cash secured. And to top it off, Karen Basbaum, the serial deal‑maker, just joined as CBO — guess why…
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Mar. 16 at 2:05 PM
$MBX CEO purchased 18,500 shares at $28.41 for a total of $525,663. Hawryluk P. Kent now owns 1,215,051 shares. https://ceo-buys.com
0 · Reply
Tomakak
Tomakak Mar. 13 at 2:38 PM
$MBX another dilution ahead, why? They have cash till 2029
0 · Reply
Benalish
Benalish Mar. 10 at 5:57 PM
$MBX
0 · Reply
Quantumup
Quantumup Mar. 2 at 12:23 PM
H.C. Wainwright⬆️ $GPCR's PT to $114 from $90 and reiterated at a Buy rating. $VKTX $LLY $NVO $MBX AZN AMGN RHHBY PFE Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2028443691505914151?s=20
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 12:23 PM
$MBX Current Stock Price: $34.80 Contracts to trade: $35.0 MBX Mar 20 2026 Call Entry: $2.50 Exit: $4.39 ROI: 76% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PamelaBarbieri520
PamelaBarbieri520 Feb. 21 at 7:19 AM
$MBX Microcap with limited disclosure and speculative trading. Fundamentals are unclear. Liquidity risk remains high.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 12:38 AM
$MBX RSI: 54.65, MACD: 0.7757 Vol: 2.19, MA20: 38.17, MA50: 34.27 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
russwise
russwise Feb. 12 at 7:38 PM
$MBX Short interest dropped again from 2.3 to 1.97 million shares.
0 · Reply
SocioCobb
SocioCobb Feb. 11 at 2:13 PM
$MBX You do the math. I find consistent 2x + bangers!
0 · Reply
NeuralNetIQ
NeuralNetIQ Feb. 4 at 1:41 PM
$MBX is a medical device company focused on ear, nose, and throat treatments; its products address niche surgical needs, limiting its total addressable market.
0 · Reply
StockConsultant
StockConsultant Feb. 2 at 2:30 PM
$MBX MBX Biosciences stock watch, pullback to 36.36 support area with high trade quality at https://stockconsultant.com/?MBX
0 · Reply
russwise
russwise Jan. 27 at 9:24 PM
$MBX Short interest down to 2.3 million shares from 3.84 million shares as of last reporting.
0 · Reply
MakeM0ney_444
MakeM0ney_444 Jan. 23 at 5:47 PM
$MBX 🤣🤣🤣
0 · Reply
SocioCobb
SocioCobb Jan. 23 at 12:32 PM
$MBX It matters who you follow!
0 · Reply
beanbamba
beanbamba Jan. 22 at 12:51 PM
$MBX
0 · Reply
Quantumup
Quantumup Jan. 20 at 4:19 PM
Guggenheim (a/o Jan. 16)⬆️ $MBX's PT to $88 from $77 and reiterated at Buy $GPCR MSTR - $PFE $VKTX NVO $LLY ASND AZN NVO Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2013646635545301488?s=20
0 · Reply
TalkMarkets
TalkMarkets Jan. 17 at 1:11 AM
Own Small Caps Or Get Left Behind In 2026 $MBX https://talkmarkets.com/content/stocks--equities/own-small-caps-or-get-left-behind-in-2026?post=550710
0 · Reply
erevnon
erevnon Jan. 16 at 3:56 PM
Guggenheim maintains MBX Biosciences $MBX at Buy and raises the price target from $77 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply